Jenna Philpott

BMS and 2seventy bio first teamed up in 2021. Credit: Moyo Studio via Getty Images. Bristol Myers Squibb (BMS) has agreed to acquire its longtime cell therapy partner 2seventy bio in a deal valued at $286m. Announced after markets closed […]

Viking is set to challenge Eli Lilly and Novo Nordisk with its investigational oral obesity drug. Credit: SOPA Images via Getty Images. Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its

If not treated, ATTRv-PN patients can lose sensation in their legs and feet. Credit: ljubaphoto via Getty Images. AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be marketed as Wainzua (eplontersen).

DBAY advisors initially approached Alliance Pharma in 2024. Credit: DjelicS via Getty Images. UK-based Alliance Pharma has agreed to a final increased cash offer from asset management company DBAY Advisors, valuing the former at approximately £362m ($467.5m). The offer, made

Kisunla and Leqembi are designed to target amyloid plaques in the brain in Alzheimer’s patients. Credit: Halfpoint Images via Getty Images. The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision not

Women make up 51% of the global population. Credit: andreswd via Getty Images. Closing the gap in health interventions between men and women could add $1tn to the global gross domestic product (GDP) – unlocking seven additional healthy years for

ITM-11 combines beta-emitting radioisotope lutetium-177 with somatostatin receptor (SSTR) agonist edotreotide. Credit: Love Employee via Getty Images. ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 (177Lu-edotreotide), after promising Phase III

Merck KGaA’s healthcare division reported 7% net sales growth in 2024. Image credit: Shutterstock/Below the Sky Merck KGaA reaffirmed its strong performance in the healthcare sector in its FY 2024 earnings report, but provided little additional information on ongoing acquisition

Dordaviprone is under review with the FDA for a rare and aggressive brain tumour. Credit: LumiNola via Getty Images. Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately $935m in cash. The deal,

A build-up of the abnormal tau can contribute to Alzheimer’s disease symptoms. Credit: Andrew Brookes via Getty Images. After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now halted its own Phase II